These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 24340715)
1. [Treatment of drug-resistant depression]. Taiminen T Duodecim; 2013; 129(20):2149-56. PubMed ID: 24340715 [TBL] [Abstract][Full Text] [Related]
2. Ketamine as an alternative treatment for treatment-resistant depression. Dowben JS; Grant JS; Keltner NL Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991 [No Abstract] [Full Text] [Related]
3. [Ketamine--a new treatment option for therapy-resistant depression]. Köhler S; Betzler F Fortschr Neurol Psychiatr; 2015 Feb; 83(2):91-7. PubMed ID: 25723773 [TBL] [Abstract][Full Text] [Related]
4. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. Paul R; Schaaff N; Padberg F; Möller HJ; Frodl T World J Biol Psychiatry; 2009; 10(3):241-4. PubMed ID: 19224412 [TBL] [Abstract][Full Text] [Related]
5. [Resistant depression]. Bertschy G Rev Med Suisse; 2007 Sep; 3(125):2072-4, 2076-7. PubMed ID: 17939525 [TBL] [Abstract][Full Text] [Related]
6. Treatment-resistant depression: no panacea, many uncertainties. Adverse effects are a major factor in treatment choice. Prescrire Int; 2011 May; 20(116):128-33. PubMed ID: 21648180 [TBL] [Abstract][Full Text] [Related]
7. Treatment escalation in patients not responding to pharmacotherapy, psychotherapy, and electro-convulsive therapy: experiences from a novel regimen using intravenous S-ketamine as add-on therapy in treatment-resistant depression. Kallmünzer B; Volbers B; Karthaus A; Tektas OY; Kornhuber J; Müller HH J Neural Transm (Vienna); 2016 May; 123(5):549-52. PubMed ID: 26721476 [TBL] [Abstract][Full Text] [Related]
8. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. Liebrenz M; Stohler R; Borgeat A World J Biol Psychiatry; 2009; 10(4 Pt 2):640-3. PubMed ID: 17853274 [TBL] [Abstract][Full Text] [Related]
9. [When depression does not end. Resistant depression: recent clinical and therapeutic aspects]. Gayetot D; Ansseau M; Triffaux JM Rev Med Liege; 2007 Feb; 62(2):103-11. PubMed ID: 17461300 [TBL] [Abstract][Full Text] [Related]
10. [The potential of group II metabotropic glutamate receptor antagonists as a novel antidepressant]. Chaki S Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Aug; 32(4):219-26. PubMed ID: 23012890 [TBL] [Abstract][Full Text] [Related]
15. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Koike H; Iijima M; Chaki S Behav Brain Res; 2011 Oct; 224(1):107-11. PubMed ID: 21669235 [TBL] [Abstract][Full Text] [Related]
16. The management of depression. The place of the new antidepressants. Part 1. General overview. Mitchell PB; Mitchell MS Aust Fam Physician; 1994 Aug; 23(8):1555-9, 1562. PubMed ID: 7980156 [TBL] [Abstract][Full Text] [Related]
17. Development of New Psychopharmacological Agents for Depression and Anxiety. Schatzberg AF Psychiatr Clin North Am; 2015 Sep; 38(3):379-93. PubMed ID: 26300029 [TBL] [Abstract][Full Text] [Related]
18. Frontiers in Therapy of Treatment-Resistant-Depression: A Future Role of Ketamine? Kwak S; Tiller D; Tucker P J Okla State Med Assoc; 2015 Mar; 108(3):88-9. PubMed ID: 26242015 [TBL] [Abstract][Full Text] [Related]
19. N-methyl-D-aspartate glutamate receptor antagonists and the promise of rapid-acting antidepressants. Krystal JH Arch Gen Psychiatry; 2010 Nov; 67(11):1110-1. PubMed ID: 21041611 [No Abstract] [Full Text] [Related]
20. Ketamine followed by memantine for the treatment of major depression. Kollmar R; Markovic K; Thürauf N; Schmitt H; Kornhuber J Aust N Z J Psychiatry; 2008 Feb; 42(2):170. PubMed ID: 18197514 [No Abstract] [Full Text] [Related] [Next] [New Search]